{"id":"W3091786344","doi":"10.1016/j.ahj.2020.09.019","title":"Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent","year":2020,"lang":"en","type":"article","venue":"American Heart Journal","topic":"Antiplatelet Therapy and Cardiovascular Diseases","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Duke Clinical Research Institute; Data Science Institute, Columbia University; Abbott Vascular; St. Jude Medical; Idorsia Pharmaceuticals; Ferring Pharmaceuticals; Novo Nordisk; Daiichi-Sankyo; Belvoir Media Group; OrbusNeich; Siemens Medical Solutions USA; Bayer Fund; Canada Excellence Research Chairs, Government of Canada; Medicines Company; Boston Scientific Corporation; Bristol-Myers Squibb; Cleveland Clinic; American College of Cardiology Foundation; Gilead Sciences; Center for Social Inclusion; Medtronic; Sanofi; Janssen Scientific Affairs; Roche; Novartis; Abbott Laboratories; CSL Behring; Chiesi Farmaceutici; Pfizer; Icahn School of Medicine at Mount Sinai; Eli Lilly and Company; Biotronik; AstraZeneca; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Merck; Mayo Clinic; Scott R. MacKenzie Foundation; Edwards Lifesciences; Roivant Sciences; Boehringer Ingelheim; Amgen","keywords":"Medicine; Conventional PCI; Percutaneous coronary intervention; Internal medicine; Myocardial infarction; Stent; Cardiology; Surgery","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03597336,0.001784834,0.001780198,0.001060565,0.001758041,0.002340577,0.001613873,0.002160908,0.004502751],"category_scores_gemma":[0.02332573,0.00150329,0.001903068,0.0007359508,0.003257098,0.001203384,0.001752377,0.003145028,0.002128425],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002130515,"about_ca_system_score_gemma":0.01033442,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009284114,"about_ca_topic_score_gemma":0.001384789,"domain_scores_codex":[0.9778898,0.01455762,0.001910477,0.002068225,0.002766611,0.0008071361],"domain_scores_gemma":[0.9893903,0.003137898,0.001566449,0.001383788,0.002256125,0.002265476],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3728711,0.05408311,0.08427181,0.006593303,0.002592589,0.0009554072,0.002930899,0.008871613,0.01255889,0.04160004,0.01730513,0.3953661],"study_design_scores_gemma":[0.4524389,0.2936673,0.09359299,0.002482061,0.004000725,0.0009680295,0.001072155,0.01626301,0.009531668,0.01518485,0.1102388,0.0005595525],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"empirical","genre_scores_codex":[0.1889677,0.002252726,0.05519313,0.004980167,0.001824485,0.7313925,0.003629805,0.0002781391,0.01148136],"genre_scores_gemma":[0.2607962,0.001141234,0.1124062,0.004393557,0.001145504,0.6154984,0.001372746,0.0000731197,0.003173031],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.03597336,"threshold_uncertainty_score":0.1902475,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03780935993126013,"score_gpt":0.3300168008840337,"score_spread":0.2922074409527736,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}